Unexpected Results From Myopia (Nearsightedness) Eye Drop Treatment Trial

Child Eye Exam Concept Art

A study by the Pediatric Eye Disease Investigator Group found that low-dose atropine eyedrops (0.01%) were no more effective than placebo in slowing the progression of myopia (nearsightedness) in children over two years. The findings contradict previous trials primarily conducted in East Asia, suggesting that racial differences may influence atropine response. The results underscore the need for more research to manage this increasingly common eye condition.

NIH-funded trial underscores the need for more research to head off high myopia.

A two-year randomized controlled trial conducted by the Pediatric Eye Disease Investigator Group (PEDIG), funded by the National Eye Institute (NEI), found that low-dose atropine eyedrops (0.01% concentration) were not more effective than placebo in slowing myopia progression in children. This contradicts findings from recent studies primarily in East Asia, which suggested that 0.01% atropine can decelerate myopia.

Use of low-dose atropine eyedrops (concentration 0.01%) was no better than placebo at slowing myopia (nearsightedness) progression and elongation of the eye among children treated for two years, according to a randomized controlled trial conducted by the Pediatric Eye Disease Investigator Group (PEDIG) and funded by the National Eye Institute (NEI). The trial aimed to identify an effective way to manage this leading and increasingly common cause of refractive error, which can cause serious uncorrectable vision loss later in life. Results from the trial were published in JAMA Ophthalmology.

Importantly, the findings contradict results from recent trials, primarily in East Asia, which showed a benefit from 0.01% atropine in slowing myopia.

“The overall mixed results on low-dose atropine show us we need more research.  Would a different dose be more effective in a US population? Would combining atropine with other strategies have a synergistic effect? Could we develop other approaches to treatment or prevention based on a better understanding of what causes myopia progression?” said Michael F. Chiang, M.D., director of the NEI, which is part of the National Institutes of Health.

Identifying an optimal approach for preventing high (advanced) myopia is urgently needed given the escalating prevalence of myopia overall and the risk of it progressing to high myopia. By 2030, it’s predicted that 39 million people in the U.S. will have myopia. By 2050, that number is expected to grow to 44 million in the U.S. and to 50% of the global population.  

Much stronger concentrations of atropine eyedrops (0.5-1.0%) have long been used by pediatric eye doctors to slow myopia progression. While effective, such doses cause light sensitivity and blurry near vision while on the nightly eyedrops. Thus, there is interest in clinical studies assessing lower concentrations that have been shown to have fewer side effects.

“The absence of a treatment benefit in our U.S.-based study, compared with East Asian studies, may reflect racial differences in atropine response. The study enrolled fewer Asian children, whose myopia progresses more quickly, and included Black children, whose myopia progresses less quickly compared with other races,” noted the study’s lead co-author, Michael X. Repka, M.D., professor of ophthalmology, Johns Hopkins University.

For the study, 187 children ages 5 to 12 years with low-to-moderate bilateral myopia were randomly assigned to use nightly atropine (0.01%) (125 children) or placebo (62 children) eyedrops for two years. Study participants, their parents, and the eye care providers were masked to the group assignments. Patient care was provided at 12 study center sites throughout the U.S.

After the treatment period, and 6 months after treatment stopped, there were no significant differences between the groups in terms of changes in degree of myopia compared with baseline. Nor were there significant differences in axial length within the two groups when compared with baseline measurements.

“It’s possible that a different concentration of atropine is needed for U.S. children to experience a benefit,” noted the study’s other lead co-author, Katherine K. Weise, O.D., professor, University of Alabama at Birmingham. “Clinical researchers could evaluate new pharmaceuticals and special wavelengths of light in combination with optical strategies, like special glasses or contact lenses, to see what works in reducing the progression of myopia.”

Among children, myopia will stabilize in about half of children around age 16 years, and among an increasingly larger percentage as they get older. By their early twenties, about 10% of individuals with myopia will continue to grow more nearsighted, and by age 24 years that percentage is 4%.

 “Vision scientists may help us figure out what’s different about the myopic eye, even among different races and ethnicities, to help create new treatment strategies,” she said. It will take a real convergence of eye research to solve the environmental, genetic, and structural mystery of myopia.”

Reference: “Randomized trial of low-dose atropine eyedrops for myopia control” by Repka MX, Weise KK, Chandler DL, Wu R, Melia BM, Manny RE,  Kehler LAF, Jordan CO, Raghuram A, Summers AI, Lee KA, Petersen DB, Erzurum SA, Pang Y, Lenhart PD, Ticho BH, Beck RW, Kraker RT, Holmes JM, Cotter SA, on behalf of the Pediatric Eye Disease Investigator Group, 13 July 2023, JAMA Ophthalmology.
DOI: 10.1001/jamaophthalmol.2023.2855

PEDIG is a collaborative network of pediatric ophthalmologists and pediatric optometrists dedicated to conducting multi-center trials on eye disorders that affect children. The trial was funded by the NEI grants EY11751, EY18810 and EY23198. The ClinicalTrials.gov identifier is NCT03334253.

Be the first to comment on "Unexpected Results From Myopia (Nearsightedness) Eye Drop Treatment Trial"

Leave a comment

Email address is optional. If provided, your email will not be published or shared.